


# Corporate Overview

WEX Pharmaceuticals Inc. (WEX) is a late stage biopharmaceutical company focused on developing Halneuron™, for the treatment of neuropathic and nociceptive pain. Halneuron is approved by the FDA and Health Canada to commence pivotal Phase 3 trials for Chemotherapy Induced Neuropathic Pain (CINP). Halneuron has demonstrated clinically meaningful effects on moderate to severe Cancer Related Pain (CRP) in previous trials.

## Halneuron™

- ▶ Active ingredient, tetrodotoxin (TTX), is a potent small molecule concentrated in creatures such as puffer fish (Not a peptide or protein)
- ▶ A sodium (Na+) channel blocker agent
- ▶ Binds to voltage-gated sodium channels on the surface of nerve cell membranes
- ▶ Acts on peripheral voltage-gated sodium channels
- ▶ Does not cross the blood-brain barrier (No effect on the central nervous system)
- ▶ Prevents and relieves pain by interrupting nerve conduction




Lead Asset	Blocks Nav 1.7	Efficacious	Safe	Market Potential
<ul style="list-style-type: none"> <li>▶ Halneuron a Phase 3 proprietary non-opioid pain therapeutic</li> <li>▶ Superior safety to opioids</li> <li>▶ No addiction, withdrawal symptoms or tolerance</li> <li>▶ Long duration of pain relief</li> </ul>	<ul style="list-style-type: none"> <li>▶ Proven blocker of voltage gated sodium channels</li> <li>▶ Specifically blocks the peripheral Nav 1.7 channel and does not affect other Nav Channels</li> <li>▶ Suppresses peripheral pain signals</li> </ul>	<ul style="list-style-type: none"> <li>▶ Successfully tested on over 700 subjects over 15 clinical trials</li> <li>▶ Converging clinical efficacy data</li> <li>▶ High probability of success in CINP and Cancer Related Pain indications</li> </ul>	<ul style="list-style-type: none"> <li>▶ Safe, well tolerated,</li> <li>▶ Side effects are mild to moderate, short in duration, not requiring medical attention</li> <li>▶ No tolerance, euphoria, sedation or addiction.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Enormous market opportunity</li> <li>▶ No drugs are approved for CINP (~\$1.25bn)</li> <li>▶ Opioids are not recommended for CINP</li> <li>▶ Non-opioid co-analgesic for Cancer Related Pain (~\$6bn)</li> </ul>

### MILESTONES TO CINP DRUG REGISTRATION

	2019	2020	2021	2022	2023
US FDA approval to commence clinical Phase III trial	✓				
US FDA Special Protocol Assessment approval of clinical Phase III trial	✓				
Health Canada approval to commence clinical Phase III trial	✓				
EMA scientific review	✓				
Breakthrough status application					
Completion of 1st pivotal clinical phase III trial					
European approval to commence clinical phase III trial					
Completion of 2nd pivotal clinical phase III trial					
CINP drug registration					★

## Market Opportunity

▶ Current treatments using anti-epileptic, anti-depressant and opioids have shown to be inadequate for the treatment of CINP. Halneuron will be the first analgesic approved for CINP which potentially captures a market of over ~\$1.25bn. Following CINP, Halneuron would likely be used for moderate to severe Cancer Related Pain which has a market potential of over ~\$6.0bn.



## Halneuron provides a pipeline of numerous indications to treat

INDICATION	DEVELOPMENT	PRE-CLINICAL	PHASE I	PHASE II	PHASE III
Chemotherapy Induced Neuropathic Pain					
Cancer Related Pain					
Burn Pain					
General Chronic Pain					
Oseteoarthritis					
Lower Back Pain					
Painful Diabetic Neuropathy					

- ▶ CINP trials planned for North America in 2019 and Europe in 2020
- ▶ Cancer Related Pain is the second indication WEX will undertake
- ▶ Future indications include osteoarthritis, back pain, post surgical pain and diabetic neuropathy

## Patents & Trademarks

- ▶ WEX protects the exclusivity of Halneuron by maintaining a family of patents related to dosage characteristics, derivatives, uses, manufacturing processes, sourcing as well as a trade secrets related to extraction, storage, and handling
- ▶ WEX continues to create and maintain patents in active pharmaceutical markets and countries



## HALNEURON™

### An attractive opportunity with enormous commercial potential

- ✓ Addresses a large unmet need in pain management
- ✓ A real response to the opioid crisis
- ✓ First CINP drug to market
- ✓ Huge pipeline for other pain indications
- ✓ Nav 1.7 is a well-validated target
- ✓ Low-risk and safe with preliminary evidence of efficacy
- ✓ Manufacturable at scale
- ✓ Strong intellectual property and trade secrets
- ✓ Experienced leadership and team

### About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a public company listed on the Hong Kong Stock Exchange (0775.HK). WEX is based in Vancouver, B.C. Canada and has operations in Canada, China and Hong Kong.

[www.wexpharma.com](http://www.wexpharma.com) for further information about the company and products.

[www.ck-lifesciences.com](http://www.ck-lifesciences.com) for further information about Wex's parent company.

#### **Forward Looking Statements**

*Certain of the statements contained in this material are forward looking statements which involve known and unknown risks, uncertainties and factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, or achievements expressed or implied.*

### Leadership

**Dr. Christopher Gallen**  
Chief Executive Officer

+1 610 656 9768

[christopherg@wexpharma.com](mailto:christopherg@wexpharma.com)

**Walter Korz**

Chief Operating Officer

+1 604 683 8868

[walterk@wexpharma.com](mailto:walterk@wexpharma.com)

**Andrew Buckland**

Chief Financial Officer

+1 858 204 3335

[andrewb@wexpharma.com](mailto:andrewb@wexpharma.com)

**Abner Yong**

Director of Finance

+1 604 676 7913

[abnery@wexpharma.com](mailto:abnery@wexpharma.com)